Jingtai Technology (XtalPi), a drug research and development company, is preparing for an initial public offering of (IPO), in the US that could raise about $400m-500m, according to people familiar with the matter.
The Shenzhen-based company is working with China Renaissance Capital Investment, China International Capital Corporation, Goldman Sachs and Jefferies.
